Company intelligence / Profile preview
Nuclidium
Basel, Switzerlandnuclidium.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Nuclidium has advanced several copper-based radiodiagnostic and therapeutic agents into Phase 1 clinical trials. Their lead programs target high-unmet need solid tumors using proprietary copper radioisotopes for both diagnosis and therapy. Early clinical data are not yet published but the company claims improved safety/efficacy profiles with their approach.
- Therapeutic areas
- OncologyEndocrinologyInfectious Diseases
- Modalities
- RadiopharmaceuticalDiagnostic radiopharmaceuticalRadionuclide drug conjugate
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Collaborates with partners across interdisciplinary fields to optimize production processes and expand supply network
Beyond the preview
Go deeper on Nuclidium.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuclidium.